LDS/Medical Tests/Olanzapine, Urine or Serum

Olanzapine, Urine or Serum

Olanzapine is an antipsychotic compound that may be used to treat the following mental illness disorders: psychotic symptoms of schizophrenia, bipolar disorders, and psychosis. It belongs to the class of compounds known as dibenzodiazepines. Schizophrenia is the main disorder that employs the use of antipsychotics for patient treatment. Schizophrenia is the most chronic major mental illness disorder in people under the age of 65.

Olanzapine is metabolized in the liver by the cytochrome 450 system, and reaches steady state plasma concentrations in 2-10 days. The half-life of Olanzapine is approximately 30 hours if given in an oral dose. Any toxic or adverse side effects of olanzapine are due to the dose of the medication and amount taken by the patient in preventing the symptoms of schizophrenia and not particularly due to the wanton drug induced “high” that other types of drugs illicit. In general the serum or plasma concentrations of antipsychotic compounds do not correlate well with clinical signs and symptoms.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient compliance
A qualitative positive result from an immunoassay type test indicates only the presence of carbamazepine and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS, or GC/MS.

Therapeutic levels: 20-80 ng/mL
Toxic levels: > 1000 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.    

Cut-Off Ranges
Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.

Stability (serum)

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for, in particular, *CYP1A2* and *CYP2D6* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Basalt RC (ed). Disposition of toxic drugs and chemicals in man, 7th ed. Foster City, CA: Biomedical Publications; 2004.
  • Bell J. Methods for monitoring neuroleptic drugs. AACC Therapeutic Drug Monitoring and Toxicology. 1985;6:1-6.
  • Levine B (ed). Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press,.Washington DC. Chapter 24, Therapeutic Drugs III: Neuroleptics (Antipsychotics). 421-434; 2013.
  • Balant-Gorgia AE and Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera. 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7): 169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4): 7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.